Please assess the completion status of the following clinical trial:

Trial Title: Artemisinin-Based Antimalarial Combinations and Clinical Response in Cameroon

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Children of either gender, aged between 6 months (\> 5kg) and 10 years.~* Suffering from acute uncomplicated P. falciparum malaria confirmed by microscopy using Giemsa-stained thick film with an asexual parasite density of 1,000 to 100,000 parasites/μl.~* Presenting with fever (axillary temperature ≥ 37.5oC) or having a history of fever in the preceding 24 hours.~* Able to ingest tablets orally (either suspended in water or uncrushed with food).~* Willing to participate in the study with written assent from parent/guardian. Parental authorization will be obtained for children less than 8 years old and documented assent of parents/guardians for children 8-10 years.~* Willing and able to attend the clinic on stipulated regular follow-up visits.~Exclusion Criteria:~•Any of the following danger signs of severe malaria: Not able to drink or breast feed Persistent vomiting (\>2 episodes within previous 24 hours) Convulsions (\>1 episode within previous 24 hours) Lethargic/unconscious~* Signs/symptoms indicating severe/complicated malaria according to WHO criteria (WHO definition).~* Concomitant illnesses, underlying chronic hepatic or renal disease, abnormal cardiac rhythm, hypoglycaemia, jaundice, respiratory distress,~* Serious gastrointestinal disease, severe malnutrition (W/H \< 70%) or severe anaemia (haemoglobin \< 5 g/dl).~* Known hypersensitivity to the study drugs.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 120 Months
- Healthy Volunteers: f

Study Arms:
- Artesunate-Amodiaquine (Type: EXPERIMENTAL): As a fixed-dose combination of artesunate-amodiaquine developed by Sanofi-Aventis (France). It has the advantage of being a 3-day regimen usable by all age groups and potentially low cost. tablets are administered per every day at dose of 25mg/67.5mg for those between 4,5kg and 9kg for 48H
- Dihydroartemisinine_Piperaquine (Type: EXPERIMENTAL): As a fixed-dose combination of dihydroartemisinin-piperaquine which is produced by Fouley (China). It is a potentially low cost 2-day regimen that has been used in children between 5-10kg as half a tablet of 40mg/320mg every day for 48H
- Artemeter-Lumefantrine (Type: ACTIVE_COMPARATOR): This is the active comparator as a fixed-dose combination of artemether and lumefantrine which is produced by Novartis (Switzerland). The drug will be used as the comparator because it is the only fixed-dose combination with artemether currently available. Administered in children as tablets containing Artemether-Lumefantrine at (20mg/120mg) for body weights of 5-10kg every 12H within 48H.

Based on this trial design, predict the completion outcome and termination type (if applicable).